XML 57 R46.htm IDEA: XBRL DOCUMENT v3.25.3
LICENSING AGREEMENTS AND ACQUISITIONS (Details)
$ in Millions
1 Months Ended 9 Months Ended 12 Months Ended
Sep. 09, 2025
USD ($)
Sep. 30, 2025
USD ($)
Jan. 31, 2025
USD ($)
therapy
Dec. 31, 2024
USD ($)
Sep. 30, 2025
USD ($)
Dec. 31, 2024
USD ($)
Sep. 30, 2024
USD ($)
Dec. 31, 2023
USD ($)
Business Combination [Line Items]                
Current portion included in Accrued and other current liabilities   $ 39     $ 39   $ 37  
Goodwill   11,287   $ 11,087 11,287 $ 11,087   $ 11,183
Whitecap Biosciences Acquisition | Bausch + Lomb                
Business Combination [Line Items]                
Payments to acquire businesses, gross     $ 28   28      
Number of innovative therapies | therapy     2          
Elios Vision | Bausch + Lomb                
Business Combination [Line Items]                
Payments to acquire businesses, gross       99        
Business combination, contingent consideration, liability       89   89    
Current portion included in Accrued and other current liabilities       11   11    
Business combination, consideration transferred           188    
Business combination, recognized asset acquired, identifiable intangible asset, excluding goodwill       177   177    
Business combination, recognized asset acquired, other asset, current       16   16    
Goodwill       $ 27   $ 27    
DURECT Corporation                
Business Combination [Line Items]                
Asset acquisition, consideration transferred   84            
Payments to acquire productive assets   64            
Asset acquisition, recognized liabilities assumed   11     11      
Asset acquisition, consideration transferred, transaction cost   9            
Asset, contingent consideration   350     $ 350      
IPRD expensed   81            
Asset acquisition, recognized assets acquired   $ 3            
Surgical Manufacturing Facility | Bausch + Lomb                
Business Combination [Line Items]                
Payments to acquire productive assets $ 75